Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Apigenin improves cytotoxicity of antiretroviral drugs against HTLV-1 infected cells through the modulation of AhR signaling.
Journal: NeuroImmune pharmacology and therapeutics
Published: November 16, 2022
Regulation of human T-cell leukemia virus type 1 antisense promoter by myocyte enhancer factor-2C in the context of adult T-cell leukemia and lymphoma.
Journal: Haematologica
Published: June 28, 2021
Can Soluble Immune Checkpoint Molecules on Exosomes Mediate Inflammation?
Journal: Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
Published: May 04, 2021
Apigenin Modulates Dendritic Cell Activities and Curbs Inflammation Via RelB Inhibition in the Context of Neuroinflammatory Diseases.
Journal: Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
Published: February 04, 2020
Potential Role of Flavonoids in Treating Chronic Inflammatory Diseases with a Special Focus on the Anti-Inflammatory Activity of Apigenin.
Journal: Antioxidants (Basel, Switzerland)
Published: November 28, 2018
MEF-2 isoforms' (A-D) roles in development and tumorigenesis.
Journal: Oncotarget
Published: November 26, 2018
Human T cell leukemia virus type 1 and Zika virus: tale of two reemerging viruses with neuropathological sequelae of public health concern.
Journal: Journal of neurovirology
Published: September 17, 2018
In vivo and in vitro immunogenicity of novel MHC class I presented epitopes to confer protective immunity against chronic HTLV-1 infection.
Journal: Vaccine
Published: April 08, 2018
Diminished TLR2-TLR9 mediated CD4+ T cell responses are associated with increased inflammation in intraocular tuberculosis.
Journal: Scientific reports
Published: January 22, 2018
FDC:TFH Interactions within Cervical Lymph Nodes of SIV-Infected Rhesus Macaques.
Journal: Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
Published: May 18, 2017
Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity.
Journal: Scientific reports
Published: November 17, 2016
Last Updated: 09/26/2026